Skip to site menu Skip to page content

Daily Newsletter

13 November 2024

Daily Newsletter

13 November 2024

Vivolta teams up with Neurochase to manufacture electrospun micro-catheters

The deal between the two is set to advance Neurochase’s Convection Enhanced Delivery designed to expedite drugs penetrating the brain.

Joshua Silverwood November 13 2024

Netherlands-based medical electrospinning company Vivolta has signed a long-term partnership with UK company Neurochase to manufacture micro-catheters thatdeliver advanced therapies to the brain.

The deal between the two will see Neurochase provided with electrospun components for the company’s micro-catheter delivery system which is designed to use electrical signals that help drugs cross over the blood-brain barrier. Dubbed the Neurochase Convection Enhanced Delivery (CED), the company is working towards what it calls a scalable system that will allow clinicians to directly target specific targets in the brain and central nervous system.

First practised in the 1990s, electrospinning is the manufacturing process by which a high-voltage power supply generates an electric field that draws charged threads of the polymer solution from a syringe needle, forming continuous metallic fibres that can have diameters as small as nanometers to micrometres in thickness.

Neurochase’s CED system comes with a catheter with a pressure gradient at its tip, allowing for a differential in air pressure that pushes the drug through the interstitial space in the brain allowing for homogenous distribution and maximising the therapeutic effect.

Sharon Kane, CEO of Neurochase said: “The VIVOLTA relationship has been hugely important in finding a solution to one of the most technically challenging components of the Neurochase delivery system. We are excited to be taking our transformative product forward together into large-scale manufacture with such a knowledgeable, skilled and motivated team.”

This form of CED drug delivery is currently being used in clinical trials to treat a range of neurological conditions, including Parkinson’s Disease, Huntington’s Disease, brain tumours, and Fronto Temporal Dementia according to the UK company, with Neurochase planning to enter clinical trials with its micro-catheter delivery system in collaboration with its clients in 2025.

Denis Leissing, CEO of VIVOLTA, said: “This partnership builds on our already successful product development work with Neurochase, establishing a long-term manufacturing relationship. It is a great example of our full suite of electrospinning solutions from product development to commercial manufacturing.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close